SolidMalignances

Head and Neck

• Phase II
  • Drug class: EGRF MAB
  • Patients enrolled: 150
• Phase III
  • Drug class: EGRF MAB
  • Patients enrolled: 400

Colorectal

• Phase II
  • Drug Class: EGRF MAB
  • Patients enrolled: 300
• Phase IV
  • Drug class: platinum derivative
  • Patients enrolled: 500

Renal

• Phase II
  • Patients enrolled: 36

• Phase IIIb
  • Drug Class: MKI
  • Patients enrolled: 2,600

Breast

• Phase III
  • Patients enrolled: 300

• Phase IIIb
  • Drug class: TKI
  • Patients enrolled: 1,100

Lung

• Phase III
  • Patients enrolled: 200

• Phase III
  • NSCLC (squamous and non squamous cell)
  • Patients enrolled: 2,200

Prostate

• Phase III
  • Drug Class: Platinum derivative
  • Patients enrolled: 900

• Phase III
  • Hormone refractory
  • Patients enrolled: 940

Gastric

• Phase III
  • Patients enrolled: 520

Exploratory Studies

• Phase I
  • Lung
  • AML
  • Gastric
  • Colorectal

HematologicMalignances

Acute Myeloid Leukemia

• Phase II
  • First Line
  • Patients enrolled: 120
• Phase II
  • First Relapse
  • Patients enrolled: 120
• Phase II
  • First Line
  • Patients enrolled: 75
• Phase III
  • Patients enrolled: 350
• Phase III
  • Vaccine
  • Patients enrolled: 250

Non-Hodgkins Lymphoma

• Phase II
  • Drug Class: MAB
  • Patients enrolled: 75

Multiple Myeloma

• Phase II/III
  • Patients enrolled: 1320